Display options
Cite
Zevin AS, Xie IY, Birse K, et al. Microbiome Composition and Function Drives Wound-Healing Impairment in the Female Genital Tract. PLoS Pathog. 2016;12(9):e1005889doi: 10.1371/journal.ppat.1005889.
Zevin, A. S., Xie, I. Y., Birse, K., Arnold, K., Romas, L., Westmacott, G., Novak, R. M., McCorrister, S., McKinnon, L. R., Cohen, C. R., Mackelprang, R., Lingappa, J., Lauffenburger, D. A., Klatt, N. R., & Burgener, A. D. (2016). Microbiome Composition and Function Drives Wound-Healing Impairment in the Female Genital Tract. PLoS pathogens, 12(9), e1005889. https://doi.org/10.1371/journal.ppat.1005889
Zevin, Alexander S, et al. "Microbiome Composition and Function Drives Wound-Healing Impairment in the Female Genital Tract." PLoS pathogens vol. 12,9 (2016): e1005889. doi: https://doi.org/10.1371/journal.ppat.1005889
Zevin AS, Xie IY, Birse K, Arnold K, Romas L, Westmacott G, Novak RM, McCorrister S, McKinnon LR, Cohen CR, Mackelprang R, Lingappa J, Lauffenburger DA, Klatt NR, Burgener AD. Microbiome Composition and Function Drives Wound-Healing Impairment in the Female Genital Tract. PLoS Pathog. 2016 Sep 22;12(9):e1005889. doi: 10.1371/journal.ppat.1005889. eCollection 2016 Sep. PMID: 27656899; PMCID: PMC5033340.
Copy Download .nbib Format: NLM
Share it on

PLoS Pathog. 2016 Sep 22;12(9):e1005889. doi: 10.1371/journal.ppat.1005889. eCollection 2016 Sep.

Microbiome Composition and Function Drives Wound-Healing Impairment in the Female Genital Tract.

PLoS pathogens

Alexander S Zevin, Irene Y Xie, Kenzie Birse, Kelly Arnold, Laura Romas, Garrett Westmacott, Richard M Novak, Stuart McCorrister, Lyle R McKinnon, Craig R Cohen, Romel Mackelprang, Jairam Lingappa, Doug A Lauffenburger, Nichole R Klatt, Adam D Burgener

Affiliations

  1. Department of Pharmaceutics, Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America.
  2. National HIV and Retrovirology Labs, JC Wilt Center for Infectious Diseases, Public Health Agency of Canada, Winnipeg, Canada.
  3. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
  4. Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America.
  5. Mass Spectrometry and Proteomics Core, National Microbiology Lab, Public Health Agency of Canada, Winnipeg, Canada.
  6. Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America.
  7. Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, California, United States of America.
  8. Department of Global Health, University of Washington, Seattle, Washington, United States of America.
  9. Department of Medicine, University of Washington, Seattle, Washington, United States of America.
  10. Department of Pediatrics, University of Washington, Seattle, Washington, United States of America.
  11. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  12. Unit of Infectious Diseases, Department of Medicine, Center for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

PMID: 27656899 PMCID: PMC5033340 DOI: 10.1371/journal.ppat.1005889

Abstract

The mechanism(s) by which bacterial communities impact susceptibility to infectious diseases, such as HIV, and maintain female genital tract (FGT) health are poorly understood. Evaluation of FGT bacteria has predominantly been limited to studies of species abundance, but not bacterial function. We therefore sought to examine the relationship of bacterial community composition and function with mucosal epithelial barrier health in the context of bacterial vaginosis (BV) using metaproteomic, metagenomic, and in vitro approaches. We found highly diverse bacterial communities dominated by Gardnerella vaginalis associated with host epithelial barrier disruption and enhanced immune activation, and low diversity communities dominated by Lactobacillus species that associated with lower Nugent scores, reduced pH, and expression of host mucosal proteins important for maintaining epithelial integrity. Importantly, proteomic signatures of disrupted epithelial integrity associated with G. vaginalis-dominated communities in the absence of clinical BV diagnosis. Because traditional clinical assessments did not capture this, it likely represents a larger underrepresented phenomenon in populations with high prevalence of G. vaginalis. We finally demonstrated that soluble products derived from G. vaginalis inhibited wound healing, while those derived from L. iners did not, providing insight into functional mechanisms by which FGT bacterial communities affect epithelial barrier integrity.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. J Virol. 2015 Sep;89(17):8793-805 - PubMed
  2. Science. 2009 Dec 18;326(5960):1694-7 - PubMed
  3. N Engl J Med. 2012 Aug 2;367(5):399-410 - PubMed
  4. Am J Reprod Immunol. 2014 Jun;71(6):555-63 - PubMed
  5. Clin Infect Dis. 2008 Dec 1;47(11):1426-35 - PubMed
  6. PLoS Med. 2012;9(6):e1001251 - PubMed
  7. Nature. 2012 Jun 13;486(7402):207-14 - PubMed
  8. Immunity. 2015 May 19;42(5):965-76 - PubMed
  9. Science. 2006 Jun 2;312(5778):1355-9 - PubMed
  10. Am J Reprod Immunol. 2011 Feb;65(2):89-98 - PubMed
  11. AIDS. 2014 Oct 23;28(16):2333-44 - PubMed
  12. Nat Immunol. 2016 May;17(5):505-13 - PubMed
  13. Am J Obstet Gynecol. 2013 Dec;209(6):505-23 - PubMed
  14. J Infect Dis. 2008 May 15;197(10 ):1361-8 - PubMed
  15. PLoS One. 2012;7(6):e37818 - PubMed
  16. Nat Methods. 2010 May;7(5):335-6 - PubMed
  17. Nat Protoc. 2007;2(2):329-33 - PubMed
  18. Am J Obstet Gynecol. 2001 Aug;185(2):375-9 - PubMed
  19. Nature. 2010 Mar 4;464(7285):59-65 - PubMed
  20. Nat Biotechnol. 2013 Sep;31(9):814-21 - PubMed
  21. J Infect Dis. 2008 May 15;197(10):1355-7 - PubMed
  22. Sex Transm Infect. 2004 Feb;80(1):8-11 - PubMed
  23. AIDS. 2008 Jul 31;22(12):1493-501 - PubMed
  24. Mucosal Immunol. 2016 May;9(3):621-33 - PubMed
  25. Microbiome. 2014 Dec 10;2(1):49 - PubMed
  26. MBio. 2015 Apr 14;6(2):null - PubMed
  27. Crit Rev Microbiol. 2004;30(3):173-85 - PubMed
  28. Int J Med Microbiol. 2015 Feb;305(2):283-6 - PubMed
  29. Nat Protoc. 2009;4(1):44-57 - PubMed
  30. J Infect Dis. 2010 Dec 15;202(12):1907-15 - PubMed
  31. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7 - PubMed
  32. ISME J. 2007 Jun;1(2):121-33 - PubMed
  33. N Engl J Med. 2005 Nov 3;353(18):1899-911 - PubMed
  34. J Infect Dis. 2015 Jun 15;211(12):1875-82 - PubMed
  35. Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40 - PubMed
  36. J Antimicrob Chemother. 2013 Nov;68(11):2648-59 - PubMed
  37. FEMS Microbiol Rev. 2013 Sep;37(5):762-92 - PubMed
  38. Curr Opin Immunol. 2015 Oct;36:22-30 - PubMed
  39. Nature. 2009 Jan 22;457(7228):480-4 - PubMed
  40. Mucosal Immunol. 2016 Jan;9(1):194-205 - PubMed

Publication Types

Grant support